CJ introduces anti-platelet therapy

CJ Corporation says it has recently launched its Anplate tablets (sarpogrelate HCl), a specific antagonist for 5-HT2A, with hope of acquiring a larger share in the domestic market.

Sarpogrelate has been proven effective for the treatment of peripheral artery diseases, and its clinical potential has been suggested for the treatment of atherosclerotic cardiovascular disease and diabetes mellit...